8-氨基-4(3H)-喹唑啉酮 | 130148-49-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 8-氨基-4(3H)-喹唑啉酮
• 英文名称: 8-aminoquinazolin-4(3H)-one
• 英文别名: 8-amino-3H-quinazolin-4-one；8-Amino-3H-chinazolin-4-on；8-amino-3H-quinazolin-4-one
• CAS: 130148-49-1
• 化学式: C₈H₇N₃O
• 分子量: 161.163
• InChiKey: PYVNSJBGHICCFN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-氨基-4(3H)-喹唑啉酮 在 sodium hydroxide 、 potassium phosphate buffer 、 三氟甲磺酸三甲基硅酯 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 8.5h， 生成 8-(β-D-ribofuranosylamino)quinazolin-4(3H)-one
  参考文献：
  名称：

  Regioselective synthesis of imidazo[4,5-g]quinazoline quinone nucleosides and quinazoline amino nucleosides. Studies of their xanthine oxidase and purine nucleoside phosphorylase substrate activity

  摘要：

  The regioselective synthesis of 3-ribofuranosylimidazo[4,5-g]quinazoline-4,8-9(3H,7H)-trione (1) (benzoquinone-stretched-out inosine) and 8-(ribofuranosylamino)quinaozlin-4(3G)-one (2) was carried out in conjunction with the design of reductive alkylating nuclosides and new purine nucleoside mimics, respectively. The preparation of 1 was carried out by regioselective ribosylation of 4-nitroimidazo[4,5-g]quinazolin-8(3H,7H)-one (3) followed by nitro group reduction, Fremy oxidation, and deacetylation. Regiocontrol of ribosylation has steric origions: the 4-nitro group of 3 directs silylation to the N(1) position, which results in ribosylation exclusively at the N(3) position under Vorbruggen reaction conditions. Regiocontrol during the preparation of 2 was possible by generating a stabilized ribofuranosyl carbocation, which selectively reacts with the amine group of the base. Nucleoside 1 is a purine-like quinone by virtue of its oxidation by xanthine oxidase. The potential inosine mimic 2 does not undergo phosphorolysis by purine nucleoside phosphorylase (PNPase), but the base form (8-amino-quinazolin-4(3H)-one) does bind to the PNPase active site as tightly as hypoxanthine. Factors which contribute to this binding behavior are discussed.

  DOI：

  10.1021/jo00002a052
• 作为产物：
  描述：

  2-氨基-3-硝基苯甲酸 在 sodium sulfide 、 水 作用下， 生成 8-氨基-4(3H)-喹唑啉酮
  参考文献：
  名称：

  Predictors and Incidence of Urinary Incontinence in Elderly Canadians With and Without Dementia — A Five-Year Follow Up: The Canadian Study of Health and Aging

  摘要：

  摘要本研究以加拿大全国健康与老龄化研究为基础，旨在确定社会人口和医疗因素、认知和功能状况对尿失禁发生的重要预测作用，并按性别和年龄组估计五年的发病率。对加拿大健康与老龄化研究（Canadian Study of Health and Aging）中于 1992 年接受临床检查并在当时排尿的参与者进行了跟踪调查，并于 1997 年再次确定了他们的尿失禁状况。分别为男性（306 人）和女性（520 人）幸存者建立了以每日尿失禁和每日或少于每日尿失禁为结果的多变量逻辑回归模型。预测变量分为以下几组：社会人口因素、认知状况、功能状况、糖尿病和中风。此外，还估算了按性别和年龄组分列的每日尿失禁和小于每日尿失禁的五年累计发生率。结果表明，女性尿失禁的发生率高于男性，而且随着年龄的增长，男女尿失禁的发生率均有所上升。尤其是在男性中，住在养老院的人比住在社区的人更容易出现尿失禁。尿失禁随痴呆症的严重程度而急剧增加，但随身体活动不便而增加。糖尿病与男性尿失禁的发生有关，但与女性无关。结论是，尿失禁在老年人中很常见，对老年人进行常规医疗和护理评估时应询问是否存在尿失禁。出现尿失禁的老年人通常患有痴呆症且身体机能受损。评估和处理的程度应根据每位患者的具体情况认真制定。

  DOI：

  10.1017/s0714980800000672

文献信息

• CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION
  申请人：Shanghai de Novo Pharmatech Co., Ltd.

  公开号：EP3854799A1

  公开（公告）日：2021-07-28

  A cyclic dinucleotide analogue, a pharmaceutical composition thereof, and application. A cyclic dinucleotide analogue (I), an isomer thereof, a prodrug, a stable isotope derivative, or a pharmaceutically acceptable salt has the following structure. The cyclic dinucleotide analogue can be used as a regulator of a stimulator of interferon genes (STING) and a related signal path thereof, and can effectively treat and/or relieve multiple types of diseases, including but not limited to malignant tumors, inflammations, autoimmune diseases, and infectious diseases. In addition, the STING regulator can also be used as a vaccine adjuvant.

  一种环二核苷酸类似物、其药物组合物及应用。一种环二核苷酸类似物（I）、其异构体、原药、稳定同位素衍生物或药学上可接受的盐具有如下结构。环二核苷酸类似物可用作干扰素基因刺激物（STING）及其相关信号通路的调节剂，可有效治疗和/或缓解多种类型的疾病，包括但不限于恶性肿瘤、炎症、自身免疫性疾病和传染性疾病。此外，STING 调节剂还可用作疫苗佐剂。
• [EN] CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION<br/>[FR] ANALOGUE DINUCLÉOTIDIQUE CYCLIQUE, COMPOSITION PHARMACEUTIQUE ASSOCIÉE ET UTILISATION<br/>[ZH] 环状二核苷酸类似物、其药物组合物及应用
  申请人：SHANGHAI DE NOVO PHARMATECH CO LTD

  公开号：WO2020057546A1

  公开（公告）日：2020-03-26

  一种环状二核苷酸类似物、其药物组合物及应用。环状二核苷酸类似物(I)、其异构体、前药、稳定的同位素衍生物或药学上可接受的盐具有如下结构。环状二核苷酸类似物可用作干扰素基因刺激因子STING及其相关信号通路的调节剂，可有效治疗和/或缓解多种类型的疾病，包括且不限于恶性肿瘤，炎症、自身免疫性疾病、传染性疾病。另外，STING调节剂还可以作为疫苗佐剂。
• [EN] OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THERFOR AND PHARMACEUTICAL APPLICATION THEREOF<br/>[FR] COMPOSÉ OXAAZAQUINAZOLINE-7(8H)-CÉTONE, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION PHARMACEUTIQUE<br/>[ZH] 氧杂氮杂喹唑啉-7(8H)-酮类化合物，其制法与医药上的用途
  申请人：GENFLEET THERAPEUTICS SHANGHAI INC

  公开号：WO2020221239A1

  公开（公告）日：2020-11-05

  一种对KRAS基因突变具有选择抑制作用的氧杂氮杂喹唑啉-7(8H)-酮类化合物及其药学上可接受的盐、立体异构体、溶剂化合物或前药，如式I或式II所示，式中各基团的定义详见说明书包含该化合物的药物组合物，及其在制备癌症药物中的应用。
• Tsuda; Oguri, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1942, vol. 62, p. 66,68; dtsch. Ref. S. 24
  作者：Tsuda、Oguri

  DOI：——

  日期：——
• Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account
  作者：Frank Wu、Frank H. Büttner、Rhonda Chen、Eugene Hickey、Scott Jakes、Paul Kaplita、Mohammed A. Kashem、Steven Kerr、Stanley Kugler、Zofia Paw、Anthony Prokopowicz、Cheng-Kon Shih、Roger Snow、Erick Young、Charles L. Cywin

  DOI：10.1016/j.bmcl.2010.04.070

  日期：2010.6

  Two closely related scaffolds were identified through an uHTS campaign as desirable starting points for the development of Rho-Kinase (ROCK) inhibitors. Here, we describe our hit-to-lead evaluation process which culminated in the rapid discovery of potent leads such as 22 which successfully demonstrated an early in vivo proof of concept for anti-hypertensive activity. (C) 2010 Elsevier Ltd. All rights reserved.